Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | EIF4A1 | P60842 | 12/20 | 0.62 |
| ▸ | DHODH | Q02127 | 3/20 | 0.59 |
| ▸ | RPA1 | P27694 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490587 | 0.88 | DHODH (0.70) | MEN1KMT2ADHODHALDH1A1GAA | |
| SCHEMBL31490577 | 0.84 | DHODH (0.65) | MEN1KMT2ADHODHALDH1A1GAA | |
| SCHEMBL6186359 | 0.80 | DHODH (0.85) | MEN1KMT2ADHODHALDH1A1GAA | |
| SCHEMBL28525057 | 0.79 | KAT8 (0.76) | MEN1KMT2ANPC1RAB9AEIF4A1 | |
| SCHEMBL29703050 | 0.79 | KAT8 (0.76) | MEN1KMT2ANPC1RAB9AEIF4A1 | |
| SCHEMBL31490621 | 0.77 | DHODH (0.73) | MEN1KMT2ANPC1RAB9AEIF4A1 | |
| SCHEMBL9788828 | 0.76 | DHODH (0.86) | MEN1KMT2ANPC1RAB9ADHODH | |
| SCHEMBL26073753 | 0.75 | DHODH (0.89) | MEN1KMT2ANPC1RAB9ADHODH | |
| SCHEMBL26073763 | 0.75 | DHODH (0.78) | MEN1KMT2ADHODHALDH1A1GAA | |
| SCHEMBL19016191 | 0.75 | EIF4A1 (0.63) | MEN1KMT2ANPC1RAB9AEIF4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200375996-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | D.E. SHAW RESEARCH, LLC (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2017106367-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | D.E. SHAW RESEARCH, LLC (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375996-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, NEDD4 | MEN1 4316/4885KMT2A 2524/4885NPC1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.